BioLife Solutions Exceeds Full Year 2025 Revenue Guidance with Strong Q4 Growth
Summary
BioLife Solutions announced preliminary unaudited revenue for Q4 and full year 2025, exceeding its previously raised annual guidance and reporting significant year-over-year growth.
Key Events
-
Exceeded Full Year Revenue Guidance
Preliminary unaudited revenue from continuing operations for 2025 reached $96.2 million, surpassing the high end of the adjusted guidance range of $95.0 million to $96.0 million.
-
Strong Q4 Revenue Growth
Fourth quarter 2025 preliminary revenue from continuing operations was $24.8 million, a 20% increase compared to $20.7 million in the prior year's fourth quarter.
-
Significant Annual Growth
Full year 2025 revenue from continuing operations increased 29% to $96.2 million from $74.6 million in 2024.
-
Positive 2026 Outlook
The company anticipates revenue growth across its product portfolio and further expansion of adjusted EBITDA margin in 2026, with full guidance expected in February.
Analysis
BioLife Solutions announced preliminary unaudited revenue for Q4 and full year 2025, exceeding its previously raised annual guidance and reporting significant year-over-year growth. The company's preliminary full-year 2025 revenue of $96.2 million surpassed the high end of its adjusted guidance range, indicating strong operational performance. The 20% year-over-year revenue growth in Q4 2025 and 29% for the full year from continuing operations highlight robust demand for its cell processing tools and services. This positive financial update, coupled with the strategic divestitures to become a pure-play cell processing company, positions BioLife Solutions for anticipated profitable growth and margin expansion in 2026.
At the time of this filing, BLFS was trading at $25.65 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $19.10 to $29.62. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.